KURA ONCOLOGY, INC. Interest and Other Income
KURA ONCOLOGY, INC. (KURA) reported Interest and Other Income of $5.03 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Income Statement › Other Income
us-gaap:InterestAndOtherIncome · last filed 2026-08-12
- KURA ONCOLOGY, INC. interest and other income for the quarter ending 2026-06-30 was $5.03M, a 27.43% decline year-over-year.
- KURA ONCOLOGY, INC. interest and other income for the quarter ending 2026-03-31 was $5.83M, a 26.06% decline year-over-year.
- KURA ONCOLOGY, INC. interest and other income for the quarter ending 2025-12-31 was $5.69M, a 0.48% increase year-over-year.
- KURA ONCOLOGY, INC. interest and other income for the quarter ending 2025-09-30 was $6.27M, a 6.48% increase year-over-year.
- KURA ONCOLOGY, INC. interest and other income for fiscal 2025 was $26.77M, a 17.18% increase from fiscal 2024.
- KURA ONCOLOGY, INC. interest and other income for fiscal 2024 was $22.85M, a 55.20% increase from fiscal 2023.
- KURA ONCOLOGY, INC. interest and other income for fiscal 2023 was $14.72M, a 246.07% increase from fiscal 2022.
- KURA ONCOLOGY, INC. interest and other income for fiscal 2022 was $4.25M, a 252.74% increase from fiscal 2021.
| Period end | Interest and Other Income 3 month | Interest and Other Income 3 month as first filed | Interest and Other Income 6 month | Interest and Other Income 6 month as first filed | Interest and Other Income 9 month | Interest and Other Income 9 month as first filed | Interest and Other Income 12 month | Interest and Other Income 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $5.03M 10-Q · filed 2026-08-12 | $10.86M 10-Q · filed 2026-08-12 | $16.55M derived: sum of 3 quarters · filed 2026-08-12 | $22.82M derived: sum of 4 quarters · filed 2026-08-12 | ||||
| 2026-03-31 | $5.83M 10-Q · filed 2026-05-12 | $11.51M derived: sum of 2 quarters · filed 2026-05-12 | $17.79M derived: sum of 3 quarters · filed 2026-05-12 | $24.72M derived: sum of 4 quarters · filed 2026-08-12 | ||||
| 2025-12-31 | $5.69M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $11.96M derived: sum of 2 quarters · filed 2026-03-05 | $18.89M derived: sum of 3 quarters · filed 2026-08-12 | $26.77M 10-K · filed 2026-03-05 | ||||
| 2025-09-30 | $6.27M 10-Q · filed 2025-11-04 | $13.21M derived: sum of 2 quarters · filed 2026-08-12 | $21.09M 10-Q · filed 2025-11-04 | $26.75M derived: sum of 4 quarters · filed 2026-08-12 | ||||
| 2025-06-30 | $6.93M 10-Q · filed 2026-08-12 | $14.81M 10-Q · filed 2026-08-12 | $20.47M derived: sum of 3 quarters · filed 2026-08-12 | $26.36M derived: sum of 4 quarters · filed 2026-08-12 | ||||
| 2025-03-31 | $7.88M 10-Q · filed 2026-05-12 | $13.54M derived: sum of 2 quarters · filed 2026-05-12 | $19.43M derived: sum of 3 quarters · filed 2026-05-12 | $25.40M derived: sum of 4 quarters · filed 2026-05-12 | ||||
| 2024-12-31 | $5.66M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $11.55M derived: sum of 2 quarters · filed 2026-03-05 | $17.52M derived: sum of 3 quarters · filed 2026-03-05 | $22.85M 10-K · filed 2026-03-05 | ||||
| 2024-09-30 | $5.89M 10-Q · filed 2025-11-04 | $11.87M derived: sum of 2 quarters · filed 2025-11-04 | $17.19M 10-Q · filed 2025-11-04 | $21.56M derived: sum of 4 quarters · filed 2026-03-05 | ||||
| 2024-06-30 | $5.97M 10-Q · filed 2025-08-07 | $11.30M 10-Q · filed 2025-08-07 | $15.67M derived: sum of 3 quarters · filed 2026-03-05 | $19.94M derived: sum of 4 quarters · filed 2026-03-05 | ||||
| 2024-03-31 | $5.33M 10-Q · filed 2025-05-01 | $9.70M derived: sum of 2 quarters · filed 2026-03-05 | $13.97M derived: sum of 3 quarters · filed 2026-03-05 | $17.19M derived: sum of 4 quarters · filed 2026-03-05 | ||||
| 2023-12-31 | $4.37M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $8.64M derived: sum of 2 quarters · filed 2026-03-05 | $11.86M derived: sum of 3 quarters · filed 2026-03-05 | $14.72M 10-K · filed 2026-03-05 | ||||
| 2023-09-30 | $4.28M 10-Q · filed 2024-11-07 | $7.49M derived: sum of 2 quarters · filed 2024-11-07 | $10.35M 10-Q · filed 2024-11-07 | $12.62M derived: sum of 4 quarters · filed 2025-02-28 | ||||
| 2023-06-30 | $3.22M 10-Q · filed 2024-08-08 | $6.08M 10-Q · filed 2024-08-08 | $8.35M derived: sum of 3 quarters · filed 2025-02-28 | $9.44M derived: sum of 4 quarters · filed 2025-02-28 | ||||
| 2023-03-31 | $2.86M 10-Q · filed 2024-05-02 | $5.13M derived: sum of 2 quarters · filed 2025-02-28 | $6.22M derived: sum of 3 quarters · filed 2025-02-28 | $6.79M derived: sum of 4 quarters · filed 2025-02-28 | ||||
| 2022-12-31 | $2.27M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $3.36M derived: sum of 2 quarters · filed 2025-02-28 | $3.92M derived: sum of 3 quarters · filed 2025-02-28 | $4.25M 10-K · filed 2025-02-28 | ||||
| 2022-09-30 | $1.09M 10-Q · filed 2023-11-02 | $1.65M derived: sum of 2 quarters · filed 2023-11-02 | $1.98M 10-Q · filed 2023-11-02 | $2.28M derived: sum of 4 quarters · filed 2024-02-27 | ||||
| 2022-06-30 | $564.00K 10-Q · filed 2023-08-09 | $893.00K 10-Q · filed 2023-08-09 | $1.19M derived: sum of 3 quarters · filed 2024-02-27 | $1.50M derived: sum of 4 quarters · filed 2024-02-27 | ||||
| 2022-03-31 | $329.00K 10-Q · filed 2023-05-10 | $624.00K derived: sum of 2 quarters · filed 2024-02-27 | $935.00K derived: sum of 3 quarters · filed 2024-02-27 | $1.23M derived: sum of 4 quarters · filed 2024-02-27 | ||||
| 2021-12-31 | $295.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $606.00K derived: sum of 2 quarters · filed 2024-02-27 | $896.00K derived: sum of 3 quarters · filed 2024-02-27 | $1.21M 10-K · filed 2024-02-27 | ||||
| 2021-09-30 | $311.00K 10-Q · filed 2022-11-03 | $601.00K derived: sum of 2 quarters · filed 2022-11-03 | $911.00K 10-Q · filed 2022-11-03 | $1.23M derived: sum of 4 quarters · filed 2023-02-23 | ||||
| 2021-06-30 | $290.00K 10-Q · filed 2022-08-03 | $600.00K 10-Q · filed 2022-08-03 | $917.00K derived: sum of 3 quarters · filed 2023-02-23 | $1.49M derived: sum of 4 quarters · filed 2023-02-23 | ||||
| 2021-03-31 | $310.00K 10-Q · filed 2022-05-04 | $302.00K 10-Q · filed 2021-05-06 | $627.00K derived: sum of 2 quarters · filed 2023-02-23 | $1.20M derived: sum of 3 quarters · filed 2023-02-23 | $2.03M derived: sum of 4 quarters · filed 2023-02-23 | |||
| 2020-12-31 | $317.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $888.00K derived: sum of 2 quarters · filed 2023-02-23 | $1.72M derived: sum of 3 quarters · filed 2023-02-23 | $2.85M 10-K · filed 2023-02-23 | $2.80M 10-K · filed 2021-02-24 | |||
| 2020-09-30 | $571.00K 10-Q · filed 2021-11-04 | $559.00K 10-Q · filed 2020-11-05 | $1.40M derived: sum of 2 quarters · filed 2021-11-04 | $2.54M 10-Q · filed 2021-11-04 | $2.50M 10-Q · filed 2020-11-05 | $3.99M derived: sum of 4 quarters · filed 2022-02-24 | ||
| 2020-06-30 | $830.00K 10-Q · filed 2021-08-05 | $818.00K 10-Q · filed 2020-08-06 | $1.96M 10-Q · filed 2021-08-05 | $1.94M 10-Q · filed 2020-08-06 | $3.42M derived: sum of 3 quarters · filed 2022-02-24 | $4.82M derived: sum of 4 quarters · filed 2022-02-24 | ||
| 2020-03-31 | $1.12M 10-Q · filed 2021-05-06 | $2.59M derived: sum of 2 quarters · filed 2022-02-24 | $3.99M derived: sum of 3 quarters · filed 2022-02-24 | $5.01M derived: sum of 4 quarters · filed 2022-02-24 | ||||
| 2019-12-31 | $1.47M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $2.87M derived: sum of 2 quarters · filed 2022-02-24 | $3.89M derived: sum of 3 quarters · filed 2022-02-24 | $4.92M 10-K · filed 2022-02-24 | $4.67M 10-K · filed 2020-02-25 | |||
| 2019-09-30 | $1.40M 10-Q · filed 2020-11-05 | $2.42M derived: sum of 2 quarters · filed 2020-11-05 | $3.45M 10-Q · filed 2020-11-05 | $4.50M derived: sum of 4 quarters · filed 2021-02-24 | ||||
| 2019-06-30 | $1.02M 10-Q · filed 2020-08-06 | $2.05M 10-Q · filed 2020-08-06 | $3.10M derived: sum of 3 quarters · filed 2021-02-24 | $4.15M derived: sum of 4 quarters · filed 2021-02-24 | ||||
| 2019-03-31 | $1.03M 10-Q · filed 2020-05-04 | $2.08M derived: sum of 2 quarters · filed 2021-02-24 | $3.13M derived: sum of 3 quarters · filed 2021-02-24 | $3.75M derived: sum of 4 quarters · filed 2021-02-24 | ||||
| 2018-12-31 | $1.05M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-24 | $2.10M derived: sum of 2 quarters · filed 2021-02-24 | $2.72M derived: sum of 3 quarters · filed 2021-02-24 | $3.17M 10-K · filed 2021-02-24 | ||||
| 2018-09-30 | $1.05M 10-Q · filed 2019-11-05 | $1.67M derived: sum of 2 quarters · filed 2019-11-05 | $2.12M 10-Q · filed 2019-11-05 | $2.42M derived: sum of 4 quarters · filed 2020-02-25 | ||||
| 2018-06-30 | $624.00K 10-Q · filed 2019-08-01 | $1.07M 10-Q · filed 2019-08-01 | $1.38M derived: sum of 3 quarters · filed 2020-02-25 | $1.57M derived: sum of 4 quarters · filed 2020-02-25 | ||||
| 2018-03-31 | $450.00K 10-Q · filed 2019-05-07 | $752.00K derived: sum of 2 quarters · filed 2020-02-25 | $949.00K derived: sum of 3 quarters · filed 2020-02-25 | $1.07M derived: sum of 4 quarters · filed 2020-02-25 | ||||
| 2017-12-31 | $302.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-25 | $499.00K derived: sum of 2 quarters · filed 2020-02-25 | $623.00K derived: sum of 3 quarters · filed 2020-02-25 | $751.00K 10-K · filed 2020-02-25 | ||||
| 2017-09-30 | $197.00K 10-Q · filed 2018-11-05 | $321.00K derived: sum of 2 quarters · filed 2018-11-05 | $449.00K 10-Q · filed 2018-11-05 | |||||
| 2017-06-30 | $124.00K 10-Q · filed 2018-08-06 | $252.00K 10-Q · filed 2018-08-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 |